Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge
1. IONS beat earnings expectations, reporting a loss of 93 cents per share. 2. First-quarter revenue increased to $132 million, outperforming market expectations. 3. Net sales for Tryngolza exceeded $6 million since U.S. approval in December 2024. 4. Strong forecast for 2025 revenue raised to $725-$750 million, enhancing investor confidence. 5. Stock prices rose 2.01% following the earnings release and positive guidance.